Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
opioid, FDA and Journavx
FDA approves 1st new class of opioid-free painkillers in over 20 years
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its root.
New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
Hosted on MSN
2h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
5h
Chocolate recall elevated to highest risk level by FDA due to risk of 'adverse health consequences’
A major chocolate recall has been upgraded to the highest possible risk level. Last month, Cal Yee Farm LCC issued a recall ...
5h
Chocolate Recall Updated to Highest Risk Level, FDA Warns Consumption Could Cause Death
The FDA has updated the December recall of some of Cal Yee Farms' products to the highest risk level classification for three ...
2d
on MSN
Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States
A recall which was issued across nine states has now been given the highest risk classification by the federal agency.
6h
Chocolate recall elevated by FDA on products sold in Tennessee. Here's what to know
Nine states have been identified as being affected by the chocolate recall, but the products were available online so others ...
verywellhealth
57m
6 Takeaways From RFK Jr.'s Confirmation Hearing: From Vaccines To Medicaid
As secretary of the HHS, Kennedy would oversee major health agencies, including the Food and Drug Administration (FDA), the ...
9h
on MSN
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Healio
1h
FDA recalls Mercury Medical T-piece resuscitator due to ventilation control component
The FDA has recalled Mercury Medical’s Neo-Tee T-Piece Resuscitator, a gas powered resuscitator intended primarily for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Popular topics
# FDA
Related topics
Trump
Washington
Journavx
Vertex Pharmaceuticals
Food and Drug Administration
Feedback